NASHUA, N.H., April 24 /PRNewswire-FirstCall/ -- iCAD(R), Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced that the Company has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its SecondLook(R) Digital CAD system supporting the GE Senographe series of Full-field Digital Mammography (FFDM) suites.
The approval, received April 9, 2007, culminates an application process similar to pre-market approval (PMA) from the United States Food and Drug Administration (FDA). iCAD is partnered with General Electric Medical Systems (GEMS) and General Electric Yokogawa Medical Systems (GEYMS) to sell SecondLook Digital in Japan.
“This approval significantly strengthens iCAD’s international market position,” said Ken Ferry, President and Chief Executive Officer of iCAD, Inc. “iCAD now enters the large Japanese market bolstered by the highly regarded GE Digital mammography brand, which will significantly increase customer acceptance of iCAD’s products.”
Using sophisticated algorithms, iCAD detection software enables earlier cancer detection which allows less invasive and more effective treatment options, enhancing patient care. iCAD’s algorithms have been shown to detect up to 72 percent of actionable missed cancers an average of 15 months earlier than mammography alone.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by almost one thousand women’s healthcare centers worldwide. For more information, call +1 877 iCAD now or visit www.icadmed.com.
For iCAD investor relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at kevin@cameronassoc.com. For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD, Inc.
CONTACT: For iCAD investor relations, Kevin McGrath of Cameron Associates,+1-212-245-4577, kevin@cameronassoc.com; or for iCAD Public Relations,Wendy Ryan of Schwartz Communications, +1-781-684-0770,icad@schwartz-pr.com
Web site: http://www.icadmed.com//
